Table I.
Changes in biochemical measurements and lumbar spine (L2-L4) BMD before and after denosumab administration.
| Measurement time point | Serum ALP (normal range, 115–359 U/l) | Serum BAP (normal range, 2.9–14.5 U/l) | Serum calcium corrected for albumin level (normal range, 8.7–10.3 mg/dl) | Serum phosphate (normal range, 2.5–4.7 mg/dl) | Urine NTX/Cr (reference range, 9.3–54.3 nMBCE/mMCr) | BMD (g/cm2) |
|---|---|---|---|---|---|---|
| Pretreatment | 627 | 66.6 | 9.3 | 3.4 | 440.5 | 1.253 |
| Post-treatment (1 week) | 524 | 57.2 | 8.8 | 1.9 | 89.4 | |
| Post-treatment (1 year) | 187 | 13.3 | 9.4 | 2.7 | 15.1 | 1.459 |
The total serum calcium was normalized to the albumin level. BMD, bone mineral density; ALP, total serum alkaline phosphatase; BAP, bone alkaline phosphatase; NTX, N-terminal cross-linked telopeptide of type I collagen; Cr, creatinine.